StockMarketWire.com - Medical device company Creo Medical said its tissue ablation device, received US Food & Drug Administration clearance.

The clearance comes after the device was successfully used for the first in-human minimally invasive edoscopic ultrasound guided treatment in a patient with an unresectable pancreatic neuroendocrine tumour in December 2020.

Following the procedure using MicroBlate Fine, the patient 'remains well [...] and subsequent scans of the patient's pancreas continue to confirm the treatment's durability,' the company said.

Story provided by StockMarketWire.com